PATENT COOPERATION TREATY

CID: 262

From the: ' INTERNATIONAL PRELIMINARY EXAMP	MALENT COOPE	RATION TREA	ry Olevasa				
To: F B Rice & Co 605 Darling Street BALMAIN NSW 2041 Applicants or agents file reference 115565/BAL	FEB 2004 PAICE & CO.	PCT WRITTEN OPINION (PCT Rule 66) Date of mailing (day/month/year) REPLY DÜE within TWO MONTHS from the above date of mailing					
International Application No. PCT/AU2003/001012	International Filing Da 11 August 2003	nte (day/month/year) Priority Date (day/month/year) 9 August 2002					
International Patent Classification (IPC) or	1 0	ation and IPC	1.3 Millian 2002				
Int. Ct. ' A61F 11/00, A61B 17/56							
Applicant	***************************************		······································				
COCHLEAR LIMITED et al-							
			•				
1. This written opinion is the first dis			ning Authority.				
2. This opinion contains indications relati	ing to the following iter	ms:,					
1 X Basis of the opinion							
II Priority							
j	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
(V Lack of unity of invention							
V X Reasoned statement under Rule explanations supporting such s	t 66.2(a)(ii) with regard t	o novelty, inventive step	or industrial applicability; citations and				
Vì Cortain documents cited							
VII Certain defects in the internation	snal application						
VIII Cortain observations on the int	emational application -						
3. The FINAL DATE by which the internation	onał preliminary examina	tion report must be estal	blished according to Rule 69.2 is:				
9 December 2004	,						
4. The applicant is hereby invited to repl	ty to this opinion.						
Witen. See the Reply Due date indicated above. However, the Australian Patent Office will not enablish the Report before the earlier of a response being filled, or (i) one month before the Final Date by which the international prelimitary sentimation report treat to enablished. The Report will take mit on become my response (dividently amendments) filled before the Report is established. If no response is filled by I ment before the Final Date, the international prelimitary quantitation expert will be evaluated to the basis of this opinion. Applicants withing to have the benefit of a forther opinion (if needed) before the report is established should enter the response is filled at least 3 months before the Final Date by which the international preliminary examination report must be established.							
How? By submitting a written reply, a For the form and the language of							
Also For an adiational opportunity in For the examiner's obligation to For an informal communication	consider amendments an	Wor arguments, see Rul	e 66.4bis.				
Name and mading address of the IPEA/AU		Authorized Officer					
AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA							
E-mail address pru@ipeusiralia.gov.su SUR THOMAS							
Facsim-le No. (02) 6285 3929 Telephone No. (02) 6283 2454							

WRITTEN OPINION

International application No.
PCT/AU2003/001012

£.	33	lasis of the opini	3R				
1.	With	ith regard to the elements of the international application:*					
		the international application as originally filed.					
		the description,	pages , as originally filed,				
			pages , filed with the demand,				
			pages , received on with the letter of .				
		the claims,	pages , as originally filed,				
			pages , as amended under Article 19,				
			pages , filed with the demand,				
			pages , received on with the letter of				
		the drawings,	pages , as originally filed,				
			pages , filed with the demand,				
			pages , received on with the letter of				
		the sequence list	ing part of the description:				
			pages , as originally filed				
			pages , filled with the demand				
			pages , received on with the latter of				
	which	the international celements were a the language of the language of	usage, all the elements marked above were available or furnished to this Authority in the language in application was filled, unless otherwise indicated under this item. valiable or fermished to this Authority in the following language which is: translation furnished for the purposes of international search (under Rule 23:1(b)). publication of the international application (under Rule 48.3(b)). he translation furnished for the purposes of international preliminary examination (under Rules 55.2				
3.			decitide and/or amino acid sequence disclosed in the international application, the written opinion he sequence listing:	was			
		contained in the	international application in printed form.				
		filed together wi	th the international application in computer readable form.				
	m	furnished subsec	neartly to this Authority in written form.				
	m.	furnished subsec	uently to this Authority in computer readable form.				
			at the subsequently furnished written sequence listing does not go beyond the disclosure in the dicarion as filed has been furnished.				
		The statement the been furnished.	at the information recorded in computer readable form is identical to the written sequence listing ha	s			
4.		The amendment	s have resulted in the cancellation of:				
		the des	cription, pages				
		the clai	rus, Nos.				
			orings, sheets/fig.				
		L. J the ara	ongs, mentarig.				

WRITTEN OPINION

International application No. PCT/A1/2003/001012

 Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	16-19, 21, 26, 32-42	YES
	Claims	1~15, 20, 22-25, 27-31	NO
Inventive step (1S)	Claims	16-19, 21, 36-40, 42	YES
	Claims	1-15, 20, 22-35, 41	NO
Industrial applicability (IA)	Claims	1-42	YES
	Claims		NO

2. Chations and explanations

The following documents identified in the International Search Report have been considered for the purposes of this report:

D1....US 6,427,086

D2....US 6.132.384

Novelty (N) Claims 1-15, 20, 22-25, 27-31

Claims 1-10, 12-15, 20, 22-25, 27-31: D1 discloses a neurostimulator (620) implantable into cavity in the cranium; the upper surface of the implant having a flange member (622) extending outwardly beyond the outward extent of the lower surface of the housing, the flange member adapted to abut the surface of the bone surrounding the cavity (column 35 lines 1 to 4).

Similarly D2 discloses the features of claims 1-5, 13, 14

Claim 11: D2 discloses a flange (158) which is an integral extension of the implant.

Inventive Step (IS) Claims 1-15, 20, 22-35, 41

Claims 1-15, 20, 22-25, 27-31 lack novelty and consequently lack inventive step.

Claims 26: Although D1 does not disclose the feature of making the flange integral with the faceplate, this would be considered obvious to a PSA and consequently lacks inventive step.

Claim 32-35: Although D1 does not disclose the feature of making the faceplate separately from the housing, this would be considered obvious to a PSA and consequently lacks inventive step.

Claim 41: Although D1 does not disclose all the steps of the method claimed, they would be considered obvious to a PSA and consequently lack inventive step.